INTI
$0.04
Inhibitor Therapeutics
$.00
15.31%
INTI
Earnings Whisper ®
N/A
Consensus:  $0.00
Revenue:  N/A
Friday
May 12
4:10 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when INTI reports earnings?
Beat
Meet
Miss

Where is INTI's stock price going from here?
Up
Flat
Down
Stock chart of INTI
Analysts
Summary of analysts' recommendations for INTI
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Inhibitor Therapeutics Inc. is a pharmaceutical development company. It discovers, develops and plans to commercialize therapeutics for cancerous and non-cancerous proliferation disorders. The company's lead product consists of SUBA-Itraconazole, a patented, oral formulation of the currently marketed, well-understood, anti-fungal drug, Itraconazole, for treatment of prostate and lung cancers, which are in clinical stage. Inhibitor Therapeutics Inc., formerly known as HedgePath Pharmaceuticals Inc., is based in Tampa, United States.